ProfileGDS5678 / 1417370_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 71% 71% 67% 71% 74% 72% 70% 70% 70% 70% 70% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5020571
GSM967853U87-EV human glioblastoma xenograft - Control 24.4367471
GSM967854U87-EV human glioblastoma xenograft - Control 34.4361971
GSM967855U87-EV human glioblastoma xenograft - Control 44.1215367
GSM967856U87-EV human glioblastoma xenograft - Control 54.484171
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7759274
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5370172
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3948170
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3720470
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3984570
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2991970
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3706870
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4363571
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4242371